Drug Profile
Zuranolone - Biogen/SAGE Therapeutics
Alternative Names: BIIB-125; S 812217; SAGE 217; SGE-797; ZURZUVAELatest Information Update: 05 Mar 2024
Price :
$50
*
At a glance
- Originator SAGE Therapeutics
- Developer Biogen; SAGE Therapeutics; Shionogi
- Class Antidepressants; Antiepileptic drugs; Antiparkinsonians; Cyclopentanes; Mood stabilisers; Nitriles; Phenanthrenes; Pyrazoles; Sleep disorder therapies; Small molecules
- Mechanism of Action GABA A receptor positive allosteric modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Seizures
Highest Development Phases
- Marketed Postnatal depression
- Preregistration Major depressive disorder
- Phase III Insomnia
- Phase II Anxiety disorders; Bipolar depression; Essential tremor; Parkinson's disease
- Discontinued Dyskinesias; Seizures
Most Recent Events
- 31 Dec 2023 Sage Therapeutics files for patent protection of production of solid forms of Zuranolone with the US Patent Office in the US and to the European Patent office
- 14 Dec 2023 Launched for Postnatal depression in USA (PO)
- 30 Nov 2023 US Drug Enforcement Administration (DEA) granted zuranolone a schedule IV classification